companie an Platz 4. Für Langfristanleger eine Bank. Bradley ist mittlerweile an der NYSE gelistet, früher an der AMEX. Pavian hat zwischendurch auch son bischen über Bradley geschrieben.
Kurs aktuell 19,12.
SYMBOL PERIOD EPS ESTIMATE EPS ACTUAL PREV. YEAR ACTUAL DATE/TIME (ET)
BDY Q2 2001 n/a $ 0.06 $ 0.02 25-Jul-01 12:00 PM
Bradley Pharmaceuticals Listed as Fourth on Fortune's 100 Fastest Growing Small Companies
TUESDAY, JULY 29, 2003 12:09 PM
- PR Newswire
FAIRFIELD, N.J., Jul 29, 2003 /PRNewswire-FirstCall via COMTEX/ -- Bradley Pharmaceuticals, Inc. (BDY) , today announced that it has been named to the Fortune Small Business annual list of the 100 fastest-growing publicly held small businesses in America, for the second consecutive year. In 2003, Bradley Pharmaceuticals ranked number 4 on the list, a significant increase over the 2002 ranking of number 46. Inclusion on the FSB 100 is based on three criteria: earnings growth, revenue growth and stock performance over the past three years.
Bradley Pharmaceuticals President and CEO Daniel Glassman stated, "The Management Team is extremely pleased that this respected financial publication has included Bradley Pharmaceuticals as the fourth fastest growing company in the Fortune Small Business category. This impressive ranking, by FSB, is particularly gratifying after Bradley has achieved several additional milestones already in the year 2003. The Company stock is now traded on the New York Stock Exchange (NYSE) and the sales force has nearly doubled from one year ago. Thus far in 2003, both operating units introduced new brands, AnaMantle(R) HC hemorrhoid treatment and Rosula(R) Aqueous Gel and Rosula(R) Aqueous Cleanser for the treatment of acne and rosacea, and more product introductions are scheduled for later in the year. Management expects that the current trend of strong sales and profit growth from inline and new brands will continue."
About FSB: Fortune Small Business FSB 100
The 2003 FSB 100 list includes 71 new companies. Combined, the included companies produced over $1 billion in net revenue. The median revenue growth rate on the list was 42% and median earnings-per-share growth was 48%. A full two-thirds of included companies were drawn from energy, healthcare and banking industries. Compiled with help from Zachs Investment Research, the FSB 100 list took into consideration only companies traded on major exchanges with $200 million or less in annual revenue and with a stock price above $1.
Bradley Pharmaceuticals, Inc. is a specialty pharmaceutical company marketing prescription niche therapies to highly targeted physician audiences in the United States and in 34 international markets. Dermatology brands are delivered by the Doak Dermatologics subsidiary and the Kenwood Therapeutics division provides gastroenterology, nutritional and respiratory therapies. Following the strategy "Acquire, Enhance, Grow" the company has achieved success by acquiring and managing the life cycle of brands that fill unmet needs.
2nd Qtr. 2003 Earnings
Thursday, July 31, 2003.
Earnings Conference Call, Thursday, July 31, 2003, at 10 AM, ET. Call 1-888-573-3046 10 minutes prior to call to participate.
Daniel Glassman will present at the Raymond James Midwest Conference scheduled for August 21, 2003, at the Glen Club, Glenview, IL.
Bradley Pharmaceuticals common stock is listed on the NYSE under the symbol BDY. Please visit Bradley Pharmaceuticals web site at: www.bradpharm.com.
Except for historical and factual information, this press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements that address activities, events or developments that Bradley expects, believes or anticipates will or may occur in the future, such as earnings estimates and predictions of future financial performance. All forward-looking statements are based on assumptions made by Bradley based on its experience and perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. These statements are subject to numerous risks and uncertainties, many of which are beyond Bradley's control, including Bradley's ability to maintain CARMOL(R) sales and bear the outcome of related pending litigation and the introduction of new and future competing products, effectively purchase or integrate new products into its portfolio or effectively react to other risks described from time to time in Bradley's SEC filings. Further, Bradley cannot predict the impact on its business of any future approvals of generic or therapeutically equivalent versions of its products or of other competing products. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Bradley undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
SOURCE Bradley Pharmaceuticals, Inc.
Anthony Griffo, Investor Relations of Bradley Pharmaceuticals,
Inc., +1-973-882-1505, ext. 313http://www.bradpharm.com
Copyright (C) 2003 PR Newswire. All rights reserved.